| Drug Type Trispecific T-cell engager (TriTE) | 
| Synonyms | 
| Target | 
| Action inhibitors, stimulants | 
| Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CD8 stimulants(Cluster of differentiation 8 stimulants) | 
| Therapeutic Areas | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| B-Cell Lymphoma | Preclinical | China  | 22 Mar 2024 | |
| B-Cell Leukemia | Preclinical | China  | - | |
| CD20 Positive B-Cell Non-Hodgkin Lymphoma | Preclinical | China  | - | 






